Literature DB >> 22425822

Combining xenon and mild therapeutic hypothermia preserves neurological function after prolonged cardiac arrest in pigs.

Michael Fries1, Anne Brücken, Ayşegül Çizen, Maren Westerkamp, Céline Löwer, Jan Deike-Glindemann, Nora K Schnorrenberger, Steffen Rex, Mark Coburn, Kay W Nolte, Joachim Weis, Rolf Rossaint, Matthias Derwall.   

Abstract

OBJECTIVE: Despite the introduction of mild therapeutic hypothermia into postcardiac arrest care, cerebral and myocardial injuries represent the limiting factors for survival after cardiac arrest. Administering xenon may confer an additional neuroprotective effect after successful cardiopulmonary resuscitation due to its ability to stabilize cellular calcium homeostasis via N-methyl-D-aspartate-receptor antagonism.
DESIGN: In a porcine model, we evaluated effects of xenon treatment in addition to therapeutic hypothermia on neuropathologic and functional outcomes after cardiopulmonary resuscitation.
SETTING: Prospective, randomized, laboratory animal study.
SUBJECTS: Fifteen male pigs.
INTERVENTIONS: Following 10 mins of cardiac arrest and 6 mins of cardiopulmonary resuscitation, ten pigs were randomized to receive either mild therapeutic hypothermia (33°C for 16 hrs) or mild therapeutic hypothermia 1 xenon (70% for 1 hr). Five animals served as normothermic controls.
MEASUREMENTS AND MAIN RESULTS: Gross hemodynamic variables were measured using right-heart catheterization. Neurocognitive performance was evaluated for 5 days after cardiopulmonary resuscitation using a neurologic deficit score before the brains were harvested for histopathological analysis. All animals survived the observation period in the mild therapeutic hypothermia 1 xenon group while one animal in each of the other two groups died. Mild therapeutic hypothermia 1 xenon preserved cardiac output during the induction of mild therapeutic hypothermia significantly better than did mild therapeutic hypothermia alone (4.6 6 0.6 L/min vs. 3.2 6 1.6 L/min, p # .05). Both treatment groups showed significantly fewer necrotic lesions in the cerebral cortex, caudate nucleus, putamen, and in hippocampal sectors CA1 and CA3/4. However, only the combination of mild therapeutic hypothermia and xenon resulted in reduced astrogliosis in the CA1 sector and diminished microgliosis and perivascular inflammation in the putamen. Clinically, only the mild therapeutic hypothermia 1 xenon-treated animals showed significantly improved neurologic deficit scores over time (day 1 = 59.0 6 27.0 vs. day 5 = 4.0 6 5.5, p ø .05) as well as in comparison to the untreated controls on days 3 through 5 after cardiopulmonary resuscitation.
CONCLUSIONS: These results demonstrate that even a short exposure to xenon during induction of mild therapeutic hypothermia results in significant improvements in functional recovery and ameliorated myocardial dysfunction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22425822     DOI: 10.1097/CCM.0b013e31823c8ce7

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  21 in total

Review 1.  [Neuroprotection by noble gases: New developments and insights].

Authors:  A V Fahlenkamp; R Rossaint; M Coburn
Journal:  Anaesthesist       Date:  2015-11       Impact factor: 1.041

Review 2.  Non-pharmaceutical therapies for stroke: mechanisms and clinical implications.

Authors:  Fan Chen; Zhifeng Qi; Yuming Luo; Taylor Hinchliffe; Guanghong Ding; Ying Xia; Xunming Ji
Journal:  Prog Neurobiol       Date:  2014-01-07       Impact factor: 11.685

Review 3.  What is the use of hypothermia for neuroprotection after out-of-hospital cardiac arrest?

Authors:  Francis Kim; Paco E Bravo; Graham Nichol
Journal:  Stroke       Date:  2015-01-06       Impact factor: 7.914

Review 4.  Brain vulnerability and viability after ischaemia.

Authors:  Stefano G Daniele; Georg Trummer; Konstantin A Hossmann; Zvonimir Vrselja; Christoph Benk; Kevin T Gobeske; Domagoj Damjanovic; David Andrijevic; Jan-Steffen Pooth; David Dellal; Friedhelm Beyersdorf; Nenad Sestan
Journal:  Nat Rev Neurosci       Date:  2021-07-21       Impact factor: 34.870

5.  Delayed argon administration provides robust protection against cardiac arrest-induced neurological damage.

Authors:  Anne Brücken; Pinar Kurnaz; Christian Bleilevens; Matthias Derwall; Joachim Weis; Kay Nolte; Rolf Rossaint; Michael Fries
Journal:  Neurocrit Care       Date:  2015-02       Impact factor: 3.210

Review 6.  Neuroprotective Properties of Xenon.

Authors:  Mervyn Maze; Timo Laitio
Journal:  Mol Neurobiol       Date:  2019-11-22       Impact factor: 5.590

Review 7.  Pharmacological Approach for Neuroprotection After Cardiac Arrest-A Narrative Review of Current Therapies and Future Neuroprotective Cocktail.

Authors:  Rishabh C Choudhary; Muhammad Shoaib; Samantha Sohnen; Daniel M Rolston; Daniel Jafari; Santiago J Miyara; Kei Hayashida; Ernesto P Molmenti; Junhwan Kim; Lance B Becker
Journal:  Front Med (Lausanne)       Date:  2021-05-18

8.  Doubling survival and improving clinical outcomes using a left ventricular assist device instead of chest compressions for resuscitation after prolonged cardiac arrest: a large animal study.

Authors:  Matthias Derwall; Anne Brücken; Christian Bleilevens; Andreas Ebeling; Philipp Föhr; Rolf Rossaint; Karl B Kern; Christoph Nix; Michael Fries
Journal:  Crit Care       Date:  2015-03-26       Impact factor: 9.097

9.  Inhaled nitric oxide improves transpulmonary blood flow and clinical outcomes after prolonged cardiac arrest: a large animal study.

Authors:  Matthias Derwall; Andreas Ebeling; Kay Wilhelm Nolte; Joachim Weis; Rolf Rossaint; Fumito Ichinose; Christoph Nix; Michael Fries; Anne Brücken
Journal:  Crit Care       Date:  2015-09-15       Impact factor: 9.097

Review 10.  A systematic review of neuroprotective strategies after cardiac arrest: from bench to bedside (Part I - Protection via specific pathways).

Authors:  Dustin B Mangus; Lei Huang; Patricia M Applegate; Jason W Gatling; John Zhang; Richard L Applegate
Journal:  Med Gas Res       Date:  2014-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.